LifeLink Ventures is involved in early-stage investments in biotech and health companies, focusing on therapies that address global health challenges. The firm connects private investors with innovative entrepreneurs self-described as working on important health solutions.

LifeLink Ventures

LifeLink Ventures | 874 followers on LinkedIn. Connecting Capital with Purpose | We are an investment firm through which private investors and corporates have direct access to exclusive life sciences investments. We look for urgently needed therapies developed by the most driven entrepreneurs and connect them with our network of investors.

We believe in the deployment of capital in alignment with a powerful cause – improvement in global health.

Afonso Sá

Co-Founder at LIFELINK Ventures I PhD I Fulbright Fellow I EMBA

Francisca Peixoto

Junior Investment Analyst @ LifeLink Ventures

Pablo Heredia

MSc Molecular Biology | PhD Biomedicine | Neuroscientist | Investment analyst

Ana Gallego Román, PhD

🥁 🥁 Another exciting addition to LifeLink's portfolio, this time in the field of cell depletion and fibrosis! Arda Therapeutics $43M Series A was led by Andreessen Horowitz (a16z) Bio with participation from Eli Lilly and Company Ventures, GV (Google Ventures) , Two Sigma Ventures , RV Invest , among other leading investors. 🔬 Arda is pioneering the use of antibody-drug conjugates and other cell-depleting modalities like T cell engagers to address forms of fibrosis, including lung scarring, and other immunology and inflammation diseases. #lifelinkportfolio #biotech #venturecapital

🔊 🔊 Promising Phase 1b/2a clinical results from our portfolio company Spiral Therapeutics ! This is incredible news for the field of inner ear disorders, where multiple challenges have slowed down the development of new therapies. #LifeLinkPortfolio #biotech #therapeutics

🎉 Welcome to the LifeLink team Ana G. Duran, PhD !! Ana is a biotechnologist with more than 8 years of R&D experience across various biomedical research fields. She earned her Master’s degree in Biomedical Sciences from Utrecht University (the Netherlands) and a Ph.D. in Regenerative Therapies from Charité University (Germany). Her doctoral research was focused on developing stem cell strategies to regenerate human heart muscle after myocardial infarction, which has resulted in several peer-reviewed publications. After completing her PhD, Ana transitioned into a role in the biotech industry. She joined a preclinical CRO as a Sales & Account Manager where she engaged with numerous leading pharma and biotech companies. In this capacity, she designed research proposals and assisted companies in obtaining critical data packages to advance their therapies into the clinic. Driven by a deep interest in biology and a strong belief in its potential to foster healthcare innovation, Ana joined LifeLink Ventures where she leverages her industry experience and scientific knowledge to contribute to due diligence on ongoing projects. #venturecapital #buildingteam #talent #LifeLinkTeam

We are excited to announce our participation in AIRNA 's oversubscribed $60 million financing. AiRNA is an incredible biotech company focused on developing RNA editing therapeutics. This investment was led by our colleagues at Forbion and ARCH Venture Partners and counted with the participation of Ono Venture Investment, Alexandria Venture Investments, ND Capital and Pathway Bioventures . The total Series A funding for AIRNA now stands at $90 million. Read more about it here: https://lnkd.in/dyFacVDZ #venturecapital #lifesciences #biotech #SeriesA #lifelinkportfolio #RNAEditing

🔥 After closing a partnership with Boehringer Ingelheim , Ochre Bio does it again! Congratulations to this extraordinary team for closing a multi-year partnership with GSK ! #LifeLinkportfolio #biotech #liverdisease #venturecapital

📌 Interesting article on how Spain may become one of the main life sciences hubs, being the country in Europe with the highest participation in clinical trials for new medicines. Check the article here 👇

🚀 We couldn't be more proud to announce Ochre Bio 's (one of LifeLink Portfolio companies) recent partnership with Boehringer Ingelheim ! This is a multi-year, multi-target $1B deal that should help bring to patients novel therapies for chronic liver disease. #biotech #LifeLink #LifeLinkPortfolio #venturecapital

📣 Check out this NYSE interview where Co-Founder & CEO Jack O'Meara explains Ochre Bio ’s role and potencial impact on liver disease treatment!

🚀 As the new Chairman of InCephalo , Dr. Lorenz Mayr brings his incredible experience in big names such as Bayer , Novartis , AstraZeneca , and Syncona. We, here at LifeLink Ventures , can’t wait to see the progress the company will make towards brain cancer treatment. #biotech #LifeLink #LifeLinkPortfolio #venturecapital

We were honoured to have Francisca Peixoto as a moderator of one of this morning's panels at BIO Europe Spring. This panel had the amazing insight and participation of Amanda Wagner , Thomas T. , Valerie Vanhooren and Jack O'Meara about the connection between VCs and Entrepreneurs and it was in collaboration with YVC Collective members Joana Correia and Ruben Sebastian-Perez . Feel free to connect with our team, Francisca Peixoto and Pablo Heredia Fontana , at the #bioeuropespring conference! #bioeuropespring #biotech #LifeLink #LifeLinkPortfolio #venturecapital #boardofdirectors #YVC

LIFE

COM:LIFELINKVENTURES

LifeLink Ventures